It was found that "Evirkhip" possesses a marked antiviral activity confirmed on a model of enteroviruses (coxsackie). The authors also studied the resistance to the drug in the chain: eukaryotic cell-viral particle-prokaryotic cell. The resistance decreased with the shift to right.